A Service For Professionals Saturday, December 16, 2017
Contact (202) 540-8337
Company News Today
A Service For Professionals Saturday, December 16, 2017 11610 Sources 421,609,185 Articles 2,875,095 Readers
Contact (202) 540-8337

Adventrx Pharmaceuticals Names CEO, COO

February 5, 2010 (FinancialWire) — Adventrx Pharmaceuticals, Inc. (AMEX: ANX) has named Brian M. Culley, previously the company’s Chief Business officer and a senior vice president, to serve as its chief executive officer.

Patrick L. Keran, who was previously the company’s General Counsel, has been named to serve as its president and chief operating officer.

Keran also will continue to serve as the company’s secretary and Principal Financial and Accounting officer.

California-based Adventrx Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Powered by EIN Presswire